GlassScriptPhysician profile
Nicholas A Lillo
NPI 1144482308
$12,805.54
in general payments reported to CMS, 2019-2025
38 companies · $2,614 in 2025
The $2,614 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,101 · 2020: $883 · 2021: $1,639 · 2022: $1,708 · 2023: $2,462 · 2024: $2,398 · 2025: $2,614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,474.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,900.20 | 2019-2025 | |
| Janssen Biotech, INC. | $1,403.53 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,287.58 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $1,075.66 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,062.21 | 2020-2025 | Xifaxan, Plenvu, Trulance |
| Celgene Corporation | $660.63 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $657.57 | 2022-2025 | Ibsrela |
| Qol Medical, LLC | $416.98 | 2020-2025 | Sucraid |
| Ironwood Pharmaceuticals, INC | $413.01 | 2019-2024 | Linzess |
| Allergan, INC. | $321.32 | 2019-2020 | |
| Lilly USA, LLC | $242.57 | 2021-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $232.26 | 2024-2025 | Voquezna |
| Genzyme Corporation | $215.08 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $184.02 | 2019-2023 | Dificid |
| Intercept Pharmaceuticals, INC. | $181.10 | 2023-2025 | Ocaliva |
Show all 37 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Lillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.